Search Results

You are looking at 51 - 60 of 1,283 items for :

  • "characteristics" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

were extracted from ClinicalTrials.gov . Of these, 500 did not meet inclusion criteria, most because they did not use a drug intervention (80%; 400/500). Trials may have been excluded for more than one reason ( Figure 1 ). Characteristics of the 215

Full access

Ashwin Shinde, Richard Li, Arya Amini, Yi-Jen Chen, Mihaela Cristea, Wenge Wang, Mark Wakabyashi, Ernest Han, Catheryn Yashar, Kevin Albuquerque, Sushil Beriwal, and Scott Glaser

backward selection of variables at a significance level of P <.10. An alpha threshold of 0.05 was chosen for statistical significance. Statistical analyses were performed using SPSS Statistics, version 24.0 (IBM Corp). Results Patient Characteristics A

Full access

Vinayak Muralidhar, Paul J. Catalano, Gally Reznor, Brandon A. Mahal, Toni K. Choueiri, Christopher J. Sweeney, Neil E. Martin, Clair J. Beard, Yu-Wei Chen, Michelle D. Nezolosky, Karen E. Hoffman, Felix Y. Feng, Quoc-Dien Trinh, and Paul L. Nguyen

, treatment, and survival data in addition to patient-specific demographic characteristics, covering 28% of the US population and 97% of incident cancers. 12 SEER was linked to Medicare administrative data, which contains insurance claims data for patients

Full access

Iman K. Berrahou, Ava Snow, Megan Swanson, and Juno Obedin-Maliver

selected because of their particular relevance to the SGM population with regard to enumeration of protections in nondiscrimination policies across federal and state laws. Analyses were performed to determine whether cancer center characteristics impacted

Full access

Ami M. Vyas, Hilary Aroke, and Stephen Kogut

explained portion of the gap is the sum of the differences between HR-positive and HR-negative women in terms of observed characteristics weighted by the pooled regression coefficients. It is calculated by multiplying the differences in the average

Full access

Ali A. Mokdad, Rebecca M. Minter, Adam C. Yopp, Matthew R. Porembka, Sam C. Wang, Hong Zhu, Mathew M. Augustine, John C. Mansour, Michael A. Choti, and Patricio M. Polanco

between 2006 and 2012 in the National Cancer Database (NCDB). The NCDB collects information from >1,500 Commission on Cancer centers and captures >70% of incident cancer cases in the United States. 11 We abstracted patient characteristics, including age

Full access

Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group

representation of the progression-free survival. Data on TTF were only available for patients with complete follow-up (diagnosis in 2015–2016). Statistical Analysis Data in this study were analyzed using SAS 9.4 (SAS Institute Inc). Baseline characteristics

Full access

Jia-Wei Lv, Yu-Pei Chen, Guan-Qun Zhou, Xu Liu, Ying Guo, Yan-Ping Mao, Jun Ma, and Ying Sun

subsequent publications, and to identify the trends of reporting quality and associated characteristics. Methods Data Source and Study Sample Data were obtained through the Aggregate Analysis of ClinicalTrials.gov (AACT) database, reflecting data

Full access

Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le

, tumor site, and baseline ESAS-r Distress score. The target sample size was 100, based on our feasibility criteria for this 1-year study. We compared patient characteristics and PROs at baseline for screen-positive versus screen-negative patients, and for

Full access

Emily J. Martin, Andrew R. Bruggeman, Vinit V. Nalawade, Reith R. Sarkar, Edmund M. Qiao, Brent S. Rose, and James D. Murphy

(18.6%) underwent esophageal stent placement. Table 1 contains baseline patient characteristics stratified by intervention. The 2 groups differed in terms of race, tumor histology, tumor location in the esophagus, age, and Charlson comorbidity index